autolus.com (AUTL) - חוב להון עצמי

Autolus Therapeutics (AUTL) develops T-cell therapies in-house while engaging third-party contractors for final trials. This chart reflects the current market value of the total debt-to-equity ratio on GURU.Markets at 5.15. The British brand is highly regarded by oncologists for the precision of its genetic modifications. The business is currently scaling sales of its first drug, expanding its clinic network and optimizing complex delivery logistics.

Autolus Therapeutics (AUTL) maintains high operational flexibility by outsourcing manufacturing and clinical trials. The absence of capital expenditures on plants is reflected in the formula through minimal debt obligations. This ratio measures the proportion of borrowed funds relative to equity to assess financial stability. The current value of 5.15 confirms the issuer's low leverage. By analyzing changes in the debt-to-equity ratio, an investor can assess the risks of balance sheet degradation.